The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

Rapid Market Growth and Projections
The advanced therapy medicinal product (ATMP) contract development and manufacturing organization (CDMO) market has experienced significant growth, expanding from $4.55 billion in 2023 to an estimated $5.30 billion in 2024. This growth represents a robust compound annual growth rate (CAGR) of 16.7%. The market’s future looks even brighter, with projections indicating it will reach $9.85 billion by 2028 at a CAGR of 16.8%.

• Current Market Size: $4.55 billion in 2023
• Projected Growth: $5.30 billion in 2024
• Forecasted Market Size: $9.85 billion by 2028

Drivers of Growth
Several factors are driving the expansion of the ATMP CDMO market:

• Increased Clinical Trials: The surge in clinical trials for ATMPs is a significant driver. Rising clinical trial numbers are critical as they test and validate innovative therapies.
• Rising Awareness: Growing recognition of the benefits of advanced therapies among researchers has bolstered demand.
• Supportive Initiatives: Government initiatives aimed at advancing medical research and therapy development contribute to market growth.

Read More On The Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Report 2024 – https://www.thebusinessresearchcompany.com/report/advanced-therapy-medicinal-products-contract-development-and-manufacturing-organization-cdmo-global-market-report

Clinical Trials: A Key Growth Factor
The increase in clinical trials is crucial for the ATMP CDMO market. Clinical trials are essential for evaluating new treatments and therapies, creating a higher demand for CDMO services. These trials ensure the scalability and quality of manufacturing processes.

• Rising Trials: For instance, in the UK, industry clinical trials increased by 4.3% from 2021 to 2022.
• Impact on CDMOs: More trials translate to higher demand for specialized manufacturing expertise and infrastructure.

Innovation in Cell Therapy Manufacturing
Advancements in cell therapy manufacturing are transforming the ATMP CDMO landscape. Companies are developing new services and technologies to address manufacturing challenges and accelerate development.

• Pluristem Therapeutics: Launched PluriCDMO, offering advanced cell therapy manufacturing with a patented 3D bioreactor system.
• Goal: Provide scalable, cost-effective cell therapies with consistent quality.

Expansions and Acquisitions
Strategic acquisitions are shaping the ATMP CDMO market, allowing companies to expand their capabilities and service offerings.

• Recipharm AB: Acquired Vibalogics in February 2022 to enhance its biologic capabilities and enter new modalities, including viral vector production.

Market Segmentation
The ATMP CDMO market is segmented by product, phase, and indication:

• By Product: Gene Therapy, Cell Therapy, Tissue Engineered
• By Phase: Phase I, Phase II, Phase III, Phase IV
• By Indication: Oncology, Cardiology, CNS & Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology & Inflammation, Ophthalmology, Hematology

Regional Insights

• North America: Led the market in 2023 due to a strong presence of major CDMOs and high R&D investments.
• Asia-Pacific: Expected to be the fastest-growing region, driven by increasing investments and emerging market players.

Conclusion
The advanced therapy medicinal product CDMO market is on an upward trajectory, driven by increasing clinical trials, technological advancements, and strategic expansions. As the industry continues to evolve, the demand for specialized CDMO services will likely surge, presenting ample opportunities for growth and innovation.

Request for A Sample Of The Global Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=15719&type=smp